BRIEF-Denali Therapeutics Announces Data Presentations On Enzyme Transportvehicle™ Programs For Hunter Syndrome, Sanfilippo Syndrome Type A And Pompe Disease At Upcoming 2026 Worldsymposium™

Reuters
Jan 30
BRIEF-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Data Presentations On Enzyme Transportvehicle™ Programs For Hunter Syndrome, Sanfilippo Syndrome Type A And Pompe Disease At Upcoming 2026 Worldsymposium™

Denali Therapeutics Inc DNLI.O:

  • DENALI THERAPEUTICS ANNOUNCES DATA PRESENTATIONS ON ENZYME TRANSPORTVEHICLE™ PROGRAMS FOR HUNTER SYNDROME, SANFILIPPO SYNDROME TYPE A AND POMPE DISEASE AT UPCOMING 2026 WORLDSYMPOSIUM™

  • DENALI THERAPEUTICS INC: FDA DECISION ON TIVIDENOFUSP ALFA BLA EXPECTED BY APRIL 5, 2026

Source text: ID:nGNX7npk2Q

Further company coverage: DNLI.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10